Ascendis Pharma A/S
ASND | NASDAQ
$238.90
+$2.18 (+0.92%)
Sep 21, 2026, 11:51 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 691.71M | 363.64M | 266.72M | 51.17M | 7.78M | 6.95M |
Cost of Revenue | 103.18M | 44.26M | 44.4M | 12.14M | 3.52M | n/a |
Gross Profit | 588.53M | 319.38M | 222.32M | 39.04M | 4.26M | 6.95M |
Operating Income | -130.89M | -278.76M | -455.54M | -561.81M | -451.79M | -330.62M |
Interest Income | 14.7M | 14.36M | 16.86M | 7.43M | 692K | 1.81M |
Pretax Income | -204.26M | -373.24M | -474.14M | -577.82M | -383.94M | -419.17M |
Net Income | -219.03M | -378.08M | -481.45M | -583.19M | -383.58M | -418.96M |
Selling & General & Admin | 435.92M | 284.55M | 258.79M | 215.85M | 160.18M | 76.67M |
Research & Development | 283.5M | 307M | 413.45M | 379.62M | 295.87M | 260.9M |
Other Expenses | n/a | 6.6M | 5.62M | 5.38M | n/a | n/a |
Operating Expenses | 719.42M | 598.15M | 677.86M | 600.85M | 456.05M | 337.57M |
Interest Expense | 77.46M | 65.5M | 44.07M | 30.68M | 3.91M | 1.92M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 822.6M | 642.4M | 722.26M | 612.99M | 459.57M | 337.57M |
Income Tax Expense | 14.78M | 4.84M | 7.3M | 5.38M | -367K | -219K |
Shares Outstanding (Basic) | 60.61M | 57.89M | 56.29M | 56.07M | 54.77M | 50.62M |
Shares Outstanding (Diluted) | 60.61M | 57.89M | 56.29M | 56.07M | 54.77M | 50.62M |
EPS (Basic) | -3.62 | -6.53 | -8.55 | -10.40 | -7 | -8.28 |
EPS (Diluted) | -3.62 | -6.53 | -8.55 | -10.40 | -7 | -8.28 |
EBITDA | -109.8M | -290.02M | -411.17M | -529.18M | -364.64M | -407.81M |
EBIT | -126.79M | -307.74M | -430.08M | -547.14M | -380.03M | -417.26M |
Depreciation & Amortization | 17M | 17.71M | 18.91M | 17.51M | 15.39M | 9.45M |
Add to Watchlist
Select watchlists to add or remove ASND